GWM
VKTX icon

GSB Wealth Management’s Viking Therapeutics VKTX Stock Holding History

GSB Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,700
Closed -$251K – 253
2026
Q1 		$251K Buy
+7,700
New +$247K 0.06% 202
2025
Q3 		– Sell
-9,205
Closed -$244K – 247
2025
Q2 		$244K Buy
9,205
+888
+11% +$23.4K 0.06% 208
2025
Q1 		$201K Buy
8,317
+907
+12% +$28.7K 0.05% 205
2024
Q4 		$298K Buy
7,410
+275
+4% +$15.7K 0.08% 177
2024
Q3 		$452K Hold
7,135
– – 0.12% 148
2024
Q2 		$378K Buy
+7,135
New +$468K 0.1% 157

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

GSB Wealth Management's VKTX Position: Q2 2026 in Review

GSB Wealth Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 7,700 shares — an estimated $251K sold.

GSB Wealth Management first reported a position in VKTX in Q2 2024 and held it in 6 quarters. The position peaked at $452K in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • GSB Wealth Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSB Wealth Management sold 7,700 Viking Therapeutics shares in Q2 2026, an estimated $251K.
  • GSB Wealth Management first reported a position in Viking Therapeutics in Q2 2024 and held it in 6 quarters.
  • GSB Wealth Management's Viking Therapeutics position peaked at $452K in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on GSB Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.